Search
carbidopa (Lodosyn)
Carbidopa is the only dopa decarboxylase inhibitor available for clinical use in the USA.
Dosage: 75-100 mg needed to adequately block decarboxylation of L-dopa
Indications:
- for use in conjunction with levodopa in carbidopa/L-dopa
Pharmacokinetics:
- does not cross blood brain barrier
Mechanism of action:
1) diminishes decarboxylation of levodopa in peripheral tissues
2) increases 1/2 life & concentration of levodopa in plasma thus increasing amount of levodopa crossing the blood brain barrier
3) blocks adverse effects of levodopa outside the brain, including orthostasis [3]
Related
benserazide (Serazide)
Specific
foscarbidopa; carbidopa phosphate
General
aromatic amino acid
catecholamine
enzyme inhibitor
pharmacologic agents for treatment of Parkinson's disease
Properties
INHIBITS: dopa decarboxylase
Database Correlations
PUBCHEM correlations
References
- Goodman and Gilman's The Pharmacological Basis of
Therapeutics, 8th ed. Gilman et al, eds.
Permagon Press/McGraw Hill, 1990. pg 471
- Bronstein J, In: Intensive Course in Geriatric Medicine &
Board Review, Marina Del Ray, CA, Sept 29-Oct 2, 2004
- Medical Knowledge Self Assessment Program (MKSAP) 19.
American College of Physicians, Philadelphia 2021
Component-of
carbidopa/entacapone/levodopa (Stalevo)
carbidopa/levodopa (Sinemet, Parcopa, Atamet, Crexont)